Eli Lilly (LLY) Enterprise Value (2009 - 2026)

Eli Lilly (LLY) has reported Enterprise Value for 18 consecutive years, with -$5.3 billion the latest figure, recorded in Q1 2026.

• Enterprise Value for Q1 2026 came in at -$5.3 billion, down 68.29% year-over-year; the trailing twelve-month figure through Mar 2026 was -$5.3 billion (down 68.29% YoY), and the FY2025 annual result was -$7.3 billion, down 117.39% from the prior year.
• Enterprise Value was -$5.3 billion for Q1 2026 at Eli Lilly, up from -$7.3 billion in the prior quarter.
• Over five years, Enterprise Value peaked at -$2.1 billion in Q4 2022 and troughed at -$9.9 billion in Q3 2025.
• Average Enterprise Value over 5 years is -$3.7 billion, with a median of -$3.1 billion recorded in 2025.
• Year-over-year, Enterprise Value soared 44.11% in 2022 and slumped 186.7% in 2025.
• Over 5 years, Enterprise Value stood at -$2.1 billion in 2022, then plunged by 35.94% to -$2.8 billion in 2023, then declined by 17.89% to -$3.3 billion in 2024, then sank by 117.39% to -$7.3 billion in 2025, then grew by 27.33% to -$5.3 billion in 2026.
• Per Business Quant data, the three most recent Enterprise Value figures were -$5.3 billion in Q1 2026, -$7.3 billion in Q4 2025, and -$9.9 billion in Q3 2025.